Immunophenotype of HIV+ patients during CD4 cell-monitored treatment interruption: Role of the IL-7/IL-7 receptor system

AIDS

Volumn 20, Issue 16, 2006, Pages 2021-2032

  Nemes, Elisa ^a   Lugli, Enrico ^a   Nasi, Milena ^a   Ferraresi, Roberta ^a   Pinti, Marcello ^a   Bugarini, Roberto ^a   Borghi, Vanni ^b   Prati, Francesca ^b   Esposito, Roberto ^b   Cossarizza, Andrea ^a   Mussini, Cristina ^b  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

HAART; IL 7 receptor system; Lymphocyte activation; Therapy interruption; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT; INTERLEUKIN 7; INTERLEUKIN 7 RECEPTOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

AGE DISTRIBUTION; ARTICLE; CELL COUNT; CLINICAL TRIAL; CYTOFLUOROMETRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPHENOTYPING; PRIORITY JOURNAL; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; APOPTOSIS; BIOLOGICAL MARKERS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOPHENOTYPING; INTERLEUKIN-7; LONGITUDINAL STUDIES; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-7; T-LYMPHOCYTE SUBSETS; VIRAL LOAD;

EID: 33750277044     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000247575.41622.b1     Document Type: Article

References (39)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860.
2. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999; 354:1112-1115.
3. Frerichs FC, Dingemans KP, Brinkman K. Cardiomyopathy with mitochondrial damage associated with nucleoside reverse-transcriptase inhibitors. N Engl J Med 2002; 347:1895-1896.
4. Côté HC, Brumme ZL, Craib KJ, Alexander CS, Wynhoven B, Ting L, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV infected patients. N Engl J Med 2002; 346:811-820.
5. Mallon PW, Miller J, Cooper DA, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 2003; 17:971-979.
6. Cossarizza A, Moyle G. Antiretroviral nucleoside and nucleotide analogues and the mitochondria. AIDS 2004; 18:137-151.
7. Dybul M, Nies-Kraske E, Daucher M, Hallahan C, Csako G, Yoder C, et al. A randomized, controlled trial of long cycle structured intermittent versus continuous ARV therapy for chronic HIV infection. Tenth Conference on Retroviruses and Opportunistic Infections. Boston, February 2003 [abstract 681b].
8. Ananworanich J, Nuesch R, Le-Braz M, Chetchotisakd P, Vibhagool A, Wicharuk S, et al. Failures of 1 week on 1 week off antiretroviral therapies in a randomized trial. AIDS 2003; 17:F33-F37.
9. Vella S, Giuliano N, Palmisano L, Bucciardini R, Andreotti M, Arcieri R, et al. ISS-PART: a prospective, randomized, multicentre clinical trial of intermittent therapy in HIV+ subjects with persistent suppression of viral replication. Tenth Conference on Retroviruses and Opportunistic Infections. Boston, February 2003 [abstract 66].
10. Cardiello PG, Hassink E, Ananworanich J, Srasuebkul P, Samor T, Mahanontharit A, et al. A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection. Clin Infect Dis 2005; 40:594-600.
11. 6 cells/l. AIDS 2002; 16:1551-1554.
12. Tarwater PM, Parish M, Gallant JE. Prolonged treatment interruption after immunologic response to highly active antiretroviral therapy. Clin Infect Dis 2003; 37:1541-1548.
13. Maggiolo F, Ripamonti D, Gregis G, Quinzan G, Callegaro A, Suter F. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trial. AIDS 2004; 18:439-446.
14. Molto J, Ruiz L, Romeu J, Martinez-Picado J, Negredo E, Tural C, et al. Influence of prior structured treatment interruptions on the length of time without antiretroviral treatment in chronically HIV-infected subjects. AIDS Res Hum Retroviruses 2004; 20:1283-1288.
15. Ananworanich J, Siangphoe U, Hill A, Cardiello P, Apateerapong W, Hirschel B, et al. Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study. J Acquir Immune Defic Syndr 2005; 39:523-529.
16. 6 cells/l. AIDS 2005; 19:287-294.
17. Mussini C, Pinti M, Bugarini R, Borghi V, Nasi M, Nemes E, et al. Effect of treatment interruption monitored by CD4 cell count on mitochondrial DNA content in HIV-infected patients: a prospective study. AIDS 2005; 19:1627-1633.
18. Nasi M, Troiano L, Lugli E, Pinti M, Ferraresi R, Monterastelli E, et al. Thymic output and functionality of the IL-7/IL-7 receptor system in centenarians: implications for the neolymphogenesis at the extreme limit of human life. Aging Cell 2006; 5:167-175.
19. Lugli E, Troiano L, Ferraresi R, Roat E, Prada N, Nasi M, et al. Characterization of cells with different mitochondrial membrane potential during apoptosis. Cytometry 2005; 68:28-35.
20. Savarino A, Bottarel F, Malavasi F, Dianzani U. Role of CD38 in HIV-1 infection: an epiphenomenon of T-cell activation or an active player in virus/host interactions? AIDS 2000; 14:1079-1089.
21. Cossarizza A, Ortolani C, Mussini C, Borghi V, Guaraldi G, Mongiardo N, et al. Massive activation of immune cells with an intact T cell repertoire in acute human immunodeficiency virus syndrome. J Infect Dis 1995; 172:105-112.
22. Pellegrin I, Thiebaut R, Blanco P, Viallard JF, Schrive MH, Merel P, et al. Can highly active antiretroviral therapy be interrupted in patients with sustained moderate HIV RNA and > 400 CD4+ cells/microl? Impact on immunovirological parameters. J Med Virol 2005; 77:164-172.
23. Liu Z, Cumberland WG, Hultin LE, Prince HE, Detels R, Giorgi JV. Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:83-92.
24. Marie-Lise Gougeon. Apoptosis as an HIV strategy to escape immune attack. Nat Rev Immunol 2003, 3:392-404.
25. Cossarizza A, Mussini C, Mongiardo N, Borghi V, Sabbatini A, De Rienzo B, et al. Mitochondria alterations and dramatic tendency to undergo apoptosis in peripheral blood lymphocytes during acute HIV syndrome. AIDS 1997; 11:19-26.
26. Cossarizza A, Stent G, Mussini C, Paganelli R, Borghi V, Nuzzo C, et al. Deregulation of the CD95/CD95L system in lymphocytes from patients with primary acute HIV infection. AIDS 2000; 14:345-355.
27. Champagne P, Ogg GS, King AS, Knabenhans C, Ellefsen K, Nobile M, et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 2001; 410:106-111.
28. Fry TJ, Mackall CL. Interleukin-7: master regulator of peripheral T-cell homeostasis? Trends Immunol 2001; 22:564-571.
29. Lang KS, Recher M, Navarini AA, Harris NL, Lohning M, Junt T, et al. Inverse correlation between IL-7 receptor expression and CD8 T cell exhaustion during persistent antigen stimulation. Eur J Immunol 2005; 35:738-745.
30. Koesters SA, Alimonti JB, Wachihi C, Matu L, Anzala O, Kimani J, et al. IL-7Ralpha expression on CD4+ T lymphocytes decreases with HIV disease progression and inversely correlates with immune activation. Eur J Immunol 2006; 36:336-344.
31. Napolitano LA, Grant RM, Deeks SG, Schmidt D, De Rosa SC, Herzenberg LA, et al. Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. Nat Med 2001; 7:73-79.
32. Jaleco S, Swainson L, Dardalhon V, Burjanadze M, Kinet S, Taylor N. Homeostasis of naive and memory CD4+ T cells: IL-2 and IL-7 differentially regulate the balance between proliferation and Fas-mediated apoptosis. J Immunol 2003; 171:61-68.
33. Geginat J, Sallusto F, Lanzavecchia A. Cytokine-driven proliferation and differentiation of human naive, central memory, and effector memory CD4(+) T cells. J Exp Med 2001; 194:1711-1719.
34. Schluns KS, Kieper WC, Jameson SC, Lefrancois L. Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat Immunol 2000; 1:426-432.
35. Colle JH, Moreau JL, Fontanet A, Lambotte O, Joussemet M, Delfraissy JF, et al. CD127 expression and regulation are altered in the memory CD8 T cells of HIV-infected patients - reversal by highly active anti-retroviral therapy (HAART). Clin Exp Immunol 2006; 143:398-403.
36. Paiardini M, Cervasi B, Albrecht H, Muthukumar A, Dunham R, Gordon S, et al. Loss of CD127 expression defines an expansion of effector CD8+ T cells in HIV-infected individuals. J Immunol 2005; 174:2900-2909.
37. Fernandez Guerrero ML, Rivas P, Molina M, Garcia R, De Gorgolas M. Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy. Clin Infect Dis 2005; 41:390-394.
38. 3. J Infect Dis 2005; 192:1787-1793.
39. El-Sadr W, Neaton J. Episodic CD4-guided use of ART is inferior to continuous therapy: results of the SMART study. Thirteenth Conference on Retroviruses and Opportunistic Infections. Denver, CO, February 2006 [abstract 1061b].